AdultPediatricDosage Forms & Strengths tablet 4mg (pack contains 24 active [white] and 4 inert [green] tablets) Contraception Progestin indicated for use by females of reproductive potential to prevent pregnancy 1 tablet qDay for 28 consecutive days; 1 white active tablet/day during the first 24 days and 1 green inert tablet/day during the 4 following days Starting with no current hormonal contraception use Take first white active tablet on the first day of menses Take subsequent white active tablets qDay at the same time each day for a total of 24 days Take 1 green inert tablet daily for 4 days and at the same time of day that active tablets were taken Begin each subsequent pack on the same day of the week as the first cycle pack (ie, on the day after taking the last inactive tablet) Switching from another contraceptive method Combined oral contraceptive (COC): Start drospirenone on the day when the new pack of the previous COC would have started Transdermal patch: Start drospirenone on the day when next application would have been scheduled Vaginal ring: Start drospirenone on the day when next insertion would have been scheduled Injection: Start drospirenone on the day when next injection would have been scheduled Intrauterine contraceptive: Start drospirenone on the day of removal Implant: Start drospirenone on the day of removal Dosage Modifications Renal or hepatic impairment: Contraindicated Dosing Considerations Consider the possibility of ovulation and conception prior to initiation of this productPremenarche: Not indicated Safety and efficacy have been established in females of reproductive age Safety and efficacy are expected to be the same for postpubertal adolescents aged <16 yr and users aged ≥16 yr Refer to adult dosingInteraction CheckerEnter a drug name and drospirenoneNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)fezolinetantdrospirenone will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitorsSerious - Use Alternative (16)amilorideamiloride and drospirenone both increase serum potassium. Avoid or Use Alternate Drug.amiloride, drospirenone. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia.belzutifanbelzutifan will decrease the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of belzutifan with hormonal contraceptives may lead to contraceptive failure or increased breakthrough bleeding. Advise females of reproductive potential to use effective nonhormonal contraception. Based on animal studies, belzutifan can cause fetal harm.calaspargase pegolcalaspargase pegol, drospirenone. unknown mechanism. Avoid or Use Alternate Drug. Due to the potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use of these drugs is not recommended. Use another non-oral contraceptive method for females of childbearing potential.eplerenonedrospirenone, eplerenone. Mechanism: pharmacodynamic synergism. Contraindicated. Hyperkalemia.fedratinibdrospirenone will increase the level or effect of fedratinib by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied.isavuconazonium sulfateisavuconazonium sulfate will increase the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.lonafarnibdrospirenone will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.mavacamtenmavacamten will decrease the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose.mobocertinibmobocertinib will decrease the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of mobocertinib with hormonal contraceptives may lead to contraceptive failure or increased breakthrough bleeding. Advise females of reproductive potential to use effective non-hormonal contraception.omaveloxoloneomaveloxolone will decrease the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Omaveloxolone may reduce efficacy of hormonal contraceptives (eg, pill, patch, ring), implants, and progestin-only pills owing to weak CYP3A4 induction.potassium acid phosphatedrospirenone and potassium acid phosphate both increase serum potassium. Avoid or Use Alternate Drug.potassium chloridedrospirenone and potassium chloride both increase serum potassium. Avoid or Use Alternate Drug.potassium citratedrospirenone and potassium citrate both increase serum potassium. Avoid or Use Alternate Drug.potassium phosphates, IVdrospirenone and potassium phosphates, IV both increase serum potassium. Avoid or Use Alternate Drug.spironolactonedrospirenone and spironolactone both increase serum potassium. Avoid or Use Alternate Drug.drospirenone, spironolactone. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia.triamterenedrospirenone and triamterene both increase serum potassium. Avoid or Use Alternate Drug.drospirenone, triamterene. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia.Monitor Closely (146)acebutololacebutolol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.aceclofenacdrospirenone and aceclofenac both increase serum potassium. Modify Therapy/Monitor Closely.acemetacindrospirenone and acemetacin both increase serum potassium. Modify Therapy/Monitor Closely.albiglutidedrospirenone decreases effects of albiglutide by passive renal tubular reabsorption due to increased pH. Use Caution/Monitor. Oral contraceptives may decrease hypoglycemic effects of antidiabetics by impairing glucose tolerance. Monitor for glycemic control in diabetic patients.albuteroldrospirenone increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.aldesleukinaldesleukin increases effects of drospirenone by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.arformoteroldrospirenone increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.aspirindrospirenone and aspirin both increase serum potassium. Modify Therapy/Monitor Closely.aspirin rectaldrospirenone and aspirin rectal both increase serum potassium. Modify Therapy/Monitor Closely.aspirin/citric acid/sodium bicarbonatedrospirenone and aspirin/citric acid/sodium bicarbonate both increase serum potassium. Modify Therapy/Monitor Closely.atazanaviratazanavir, drospirenone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Atazanavir may increase or decrease levels of drospirenone. Use alternatives if available.atenololatenolol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.atogepantdrospirenone will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.avapritinibdrospirenone will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.axitinibdrospirenone increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.benazeprilbenazepril and drospirenone both increase serum potassium. Use Caution/Monitor.bendroflumethiazidedrospirenone increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.betaxololbetaxolol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.bisoprololbisoprolol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.bumetanidedrospirenone increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.canagliflozindrospirenone and canagliflozin both increase serum potassium. Use Caution/Monitor.candesartancandesartan and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.captoprilcaptopril, drospirenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.carbamazepinecarbamazepine will decrease the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Advise patients to use alternative contraceptive method during coadministration; continue alternative contraception for 28 days after discontinuing therapy to ensure contraception reliability carbenoxolonedrospirenone increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.carvedilolcarvedilol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.celecoxibdrospirenone and celecoxib both increase serum potassium. Modify Therapy/Monitor Closely.celiprololceliprolol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.chlorothiazidedrospirenone increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.chlorthalidonedrospirenone increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.choline magnesium trisalicylatedrospirenone and choline magnesium trisalicylate both increase serum potassium. Modify Therapy/Monitor Closely.clobazamclobazam will decrease the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clobazam is a weak CYP3A4 inducer; effectiveness of hormonal contraceptives may be diminished when given concurrently with clobazam. Additional non-hormonal forms of contraception are recommended.cyclopenthiazidedrospirenone increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.cyclosporinedrospirenone, cyclosporine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Monitor serum cyclosporine concentrations, and for signs and symptoms of renal and hepatic toxicity.darunavirdarunavir will increase the level or effect of drospirenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended.diclofenacdrospirenone and diclofenac both increase serum potassium. Modify Therapy/Monitor Closely.diflunisaldrospirenone and diflunisal both increase serum potassium. Modify Therapy/Monitor Closely.digoxindrospirenone and digoxin both increase serum potassium. Modify Therapy/Monitor Closely.disopyramidedrospirenone increases effects of disopyramide by pharmacodynamic synergism. Use Caution/Monitor. Additive cardiovascular depression.dobutaminedrospirenone increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.dopexaminedrospirenone increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.enalaprilenalapril, drospirenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.ephedrinedrospirenone increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.epinephrinedrospirenone increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.epinephrine racemicdrospirenone increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.eprosartaneprosartan and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.esmololesmolol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.ethacrynic aciddrospirenone increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.etodolacdrospirenone and etodolac both increase serum potassium. Modify Therapy/Monitor Closely.exenatide injectable solutiondrospirenone, exenatide injectable solution. Other (see comment). Use Caution/Monitor. Comment: Oral contraceptives may decrease hypoglycemic effects of antidiabetics by impairing glucose tolerance. The effect of exenatide to slow gastric emptying may reduce the extent and rate of oral medications that require rapid GI absorption. Advise patients to take oral contraceptives at least 1 hr before exenatide. .exenatide injectable suspensiondrospirenone, exenatide injectable suspension. Other (see comment). Use Caution/Monitor. Comment: Oral contraceptives may decrease hypoglycemic effects of antidiabetics by impairing glucose tolerance. The effect of exenatide to slow gastric emptying may reduce the extent and rate of oral medications that require rapid GI absorption. Advise patients to take oral contraceptives at least 1 hr before exenatide.fenbufendrospirenone and fenbufen both increase serum potassium. Modify Therapy/Monitor Closely.fenoprofendrospirenone and fenoprofen both increase serum potassium. Modify Therapy/Monitor Closely.finerenonedrospirenone will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.drospirenone and finerenone both increase serum potassium. Modify Therapy/Monitor Closely. Finerenone dose adjustment based on current serum potassium concentration. Monitor serum potassium and adjust finerenone dose as described in the prescribing information as necessary.flibanserindrospirenone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flurbiprofendrospirenone and flurbiprofen both increase serum potassium. Modify Therapy/Monitor Closely.formoteroldrospirenone increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.fosinoprilfosinopril, drospirenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.furosemidedrospirenone increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.gentamicindrospirenone increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.hydrochlorothiazidedrospirenone increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.ibuprofendrospirenone and ibuprofen both increase serum potassium. Modify Therapy/Monitor Closely.ibuprofen IVdrospirenone and ibuprofen IV both increase serum potassium. Modify Therapy/Monitor Closely.imidaprilimidapril, drospirenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.indapamidedrospirenone increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.indomethacindrospirenone and indomethacin both increase serum potassium. Modify Therapy/Monitor Closely.irbesartanirbesartan and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.isoproterenoldrospirenone increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.ivacaftordrospirenone increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .juniperjuniper, drospirenone. Other (see comment). Use Caution/Monitor. Comment: Juniper may potentiate or interfere with diuretic therapy. Juniper has diuretic effects, but may cause kidney damage at large doses.ketoprofendrospirenone and ketoprofen both increase serum potassium.